Design and synthesis of Aza-boeravinone derivatives as potential novel topoisomerase I inhibitors
作者:Yong Zhou、Yin-Peng Bai、Mi Zhang、Jian-Mei Gao、Cheng-Jie Yang、Zhi-Jun Zhang、Nan Deng、Lei Li、Ying-Qian Liu、Chuan-Rui Xu
DOI:10.1016/j.bioorg.2022.105747
日期:2022.5
phase and cell apoptosis, but also dose-dependently inhibited topoisomerase I activity and induced DNA damage in HepG2 cells. Molecular docking showed that ZML-8 and ZML-14 could interact with topoisomerase I-DNA complex with a similar binding mode to Topotecan. Inhibitory activities of these two compounds on topoisomerase I were then confirmed in both cell-free systems and in whole-cell lysates. Taken
基于天然产物boeravinones的结构骨架,采用氮原子取代策略设计合成了两种6 H-色烯并[3,4- b ]喹啉衍生物。然后,针对六种人类肿瘤细胞系评估它们的细胞毒活性,包括 HepG2(肝细胞癌)、A2780(卵巢癌)、Hela(宫颈癌)、HCT116(结直肠癌)、SW1990(胰腺癌)和 MCF7(乳腺癌) . 结果表明,化合物ZML-8和ZML-14对HepG2细胞具有很强的抑制活性,IC 50值分别为0.58和1.94 μM。此外,ZML-8和ZML-14对 HepG2 和 L-02 细胞的选择性高于 Topotecan。机制上,ZML-8和ZML-14不仅诱导细胞周期停滞在 G2/M 期和细胞凋亡,而且剂量依赖性地抑制 HepG2 细胞的拓扑异构酶 I 活性并诱导 DNA 损伤。分子对接表明ZML-8和ZML-14可以与拓扑异构酶I-DNA复合物相互作用,结合方式与拓扑替康相